Compare RLX Technology Inc (RLX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? RLX Technology Inc trades at $1.72 (market cap $2.10B), while Vertex Pharmaceuticals Incorporated trades at $508.04 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 60.7× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 34 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RLX | VRTX | |
|---|---|---|
Market Cap | $2.10B | $127.55B |
Volume | 1,079,706 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $557.96 |
52-Week Low | $1.68 | $407.37 |
Typical Hold Time | 34 Days | 120 Days |
Enterprise Value | $832.26M | $121.68B |
Dividend Yield | 5.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.73, showing no change in the latest session and recently hitting 52-week lows. The stock exhibits bearish technical signals with mixed fundamentals - revenue grew to $3.62B in 2025 with strong 21.87% net margins, but recent quarters show consistent earnings misses. Analyst coverage remains limited with a single hold rating, while cash flow trends show volatility with negative net cash flow in 2025.
RLX faces near-term headwinds from earnings underperformance and technical weakness, though valuation appears reasonable with P/E of 15.46 and P/B below 1.0. International expansion provides growth potential, but regulatory risks and margin compression require monitoring for sustained recovery.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
